Product Description
Tonix is developing TNX-1700 (rTFF2-CTP) for the treatment of gastric and colon cancers under a license from Columbia University. Columbia was recently granted patent claims, which, excluding possible patent term extensions, is expected to provide U.S. market exclusivity until April 2, 2033. (Sourced from: https://www.globenewswire.com/news-release/2021/12/13/2350632/28908/en/Tonix-Pharmaceuticals-Announces-Research-Collaboration-with-Columbia-University-to-Study-Recombinant-Trefoil-Factor-2-rTFF2-Based-Therapy-TNX-1700-for-Gastric-and-Colorectal-Cancer.html)
Mechanisms of Action: TFF2 Agonist
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Tonix Pharmaceuticals
Company Location: Eastern America
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|